전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved104 programs
CGTLimited DatastaleShanghai Mingju Biotechnology C…Phase 1

JWCAR029 (JWCAR029)

Non Hodgkin Lymphoma · Non Hodgkin Lymphoma

#NonHodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 14Status Active
AntibodyLimited DatastaleBristol-Myers SquibbPhase 2

Lirilumab (Lirilumab)

Non-Hodgkin's Lymphoma; Hodgkin Lymphoma · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#Antibody#Phase2#monoclonal-antibody#Non-HodgkinsLymphoma+2
Trials 13Status Active
CGTLimited DatastaleShanghai AbelZeta Ltd.Phase 1

C-CAR011 (C-CAR011)

Refractory or Relapsed Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 6Status Active
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

anti-CD5 CAR T cells (anti-CD5 CAR T cells)

T-cell Acute Lymphoblastic Leukemia; T-cell Non-Hodgkin Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 6Status Active
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

RNA anti-CD19 CAR T cells (RNA anti-CD19 CAR T cells)

Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 4Status Discontinued
AntibodyLimited DatastaleHoffmann-La RochePhase 2

Rituxumab (Rituxumab)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#monoclonal-antibody#Hoffmann-La
Trials 4Status Active
AntibodyLimited DatastaleGenentech, Inc.Phase 2

Bispecific antibody-based combined with CAR-T cell therapy (Bispecific antibody-based combined with CAR-T cell therapy)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#monoclonal-antibody#Genentech
Trials 3Status Recruiting
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin, anti-PD-1 antibody.)

Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#IneligibleOrRefusedTransplantPat+1
Trials 3Status Recruiting
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

RNA CART19 cells (CD19 RNA redirected autologous T-cells, CD19 RNA redirected autologous T-cells (RNA CART19 cells))

Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 3Status Discontinued
CGTLimited DatastaleBaylor College of MedicinePhase 1

CD30.CAR-EBVST cells (CD30.CAR-EBVST cells)

Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type; Classical Hodgkin Lymphoma · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 3Status Discontinued
CGTLimited DatastaleUniversity of Colorado, DenverPhase 1

UCD19 CAR T Cells (UCD19 CAR T Cells)

Non Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 2

12-Day Production of Car-T Cells (12-Day Production of Car-T Cells)

Non Hodgkin Lymphoma (NHL); Mantle Cell Lymphoma (MCL) · Non Hodgkin Lymphoma (NHL)

#NonHodgkinLymphomaNHL#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
CGTLimited DatastaleJuno Therapeutics, Inc., a Bris…Phase 1

Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes)

Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent B-Cell Non-Hodgkin Lymphoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 2Status Discontinued
CGTLimited DatastaleYake Biotechnology Ltd.Phase 1

CD19-BAFF Targeted CAR T-cells (CD19-BAFF Targeted CAR T-cells)

Acute Lymphoblastic Leukemia,B-Cell; Non-hodgkin Lymphoma,B Cell · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 2Status Recruiting
CGTLimited DatastaleTimmune Biotech Inc.Phase 1

CD19-TriCAR-T/SILK (CD19-TriCAR-T/SILK)

Non-Hodgkin Lymphoma of Intestine; Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 2Status Active
CGTLimited DatastaleUniversity of Colorado, DenverPhase 1

CD19x22 CAR T Cells (CD19x22 CAR T Cells)

Non-Hodgkin Lymphoma; B-cell Non-Hodgkin Lymphoma (B-NHL) · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Induction without Brentuximab Vedotin)

Hodgkin Lymphoma, Adult · Hodgkin Lymphoma, Adult

#HodgkinLymphomaAdult#ADC#Phase2#antibody-drug-conjugate#HodgkinLymphoma+2
Trials 2Status Recruiting
CGTLimited DatastaleJuno Therapeutics, a Subsidiary…Phase 2

JCARH125 (JCARH125)

Non Hodgkin Lymphoma; Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 2Status Active
CGTLimited DatastaleSana BiotechnologyPhase 1

SC291 (SC291)

Non Hodgkin Lymphoma; Chronic Lymphocytic Leukemia · Lupus Erythematosus

#LupusErythematosus#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 2Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

anti-CD19 IL10/IL15 CAR-NK (anti-CD19 IL10/IL15 CAR-NK)

B-cell Non Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 2Status Recruiting

2 / 6 pages

← PreviousNext →